Bailard’s Novartis NVS Stock Holding History

Bailard’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Buy	13,869 +587	+4%	+$88K	0.04%	250
2026 Q1	$2.03M	Sell	13,282 -1,144	-8%	-$175K	0.05%	231
2025 Q4	$1.99M	Buy	14,426 +2,305	+19%	+$302K	0.04%	229
2025 Q3	$1.55M	Buy	12,121 +1,418	+13%	+$173K	0.03%	272
2025 Q2	$1.3M	Buy	10,703 +580	+6%	+$65.4K	0.03%	291
2025 Q1	$1.13M	Buy	10,123 +4,160	+70%	+$443K	0.03%	290
2024 Q4	$580K	Buy	5,963 +283	+5%	+$30.2K	0.01%	431
2024 Q3	$653K	Buy	5,680 +1,593	+39%	+$181K	0.02%	414
2024 Q2	$435K	Buy	4,087 +661	+19%	+$66.4K	0.01%	479
2024 Q1	$331K	Buy	+3,426	New	+$351K	0.01%	542
2021 Q1	–	Sell	-9,088	Closed	-$858K	–	727
2020 Q4	$858K	Buy	9,088 +550	+6%	+$48.1K	0.04%	236
2020 Q3	$742K	Buy	8,538 +485	+6%	+$42K	0.04%	234
2020 Q2	$703K	Buy	8,053 +3,102	+63%	+$268K	0.04%	225
2020 Q1	$408K	Sell	4,951 -956	-16%	-$85.3K	0.03%	258
2019 Q4	$559K	Sell	5,907 -33	-0.6%	-$2.96K	0.03%	257
2019 Q3	$516K	Buy	5,940 +600	+11%	+$53.9K	0.03%	263
2019 Q2	$487K	Buy	5,340 +172	+3%	+$14.6K	0.03%	290
2019 Q1	$446K	Buy	+5,168	New	+$415K	0.03%	324

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bailard's NVS Position: Q2 2026 in Review

Bailard increased its Novartis (NVS) stake by 4.4% in Q2 2026, buying an estimated $88K and bringing the position to 13,869 shares worth $2.17M. The position accounts for 0.04% of the portfolio, ranked #250.

Bailard first reported a position in NVS in Q1 2019 and has held it in 18 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Bailard held 13,869 shares of Novartis worth $2.17M as of Q2 2026.
Bailard bought 587 Novartis shares in Q2 2026, an estimated $88K.
Novartis made up 0.04% of Bailard's portfolio in Q2 2026, its #250 holding.
Bailard first reported a position in Novartis in Q1 2019 and has held it in 18 quarters since.
1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.